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fast track
The best solution  
is to order each  
test for a reason, 
which would  
reduce the number 
of false positives
How should you evaluate  
elevated calcium in an  
asymptomatic patient?
Evidence-based answer
First,	establish	that	true	hypercalcemia	
exists	by	repeating	the	serum	calcium	and	
measuring	or	calculating	the	physiologically	
active	serum	calcium	when	abnormalities	
in	blood	pH	or	albumin	are	found	(sor:	C,	
expert	opinion).	patients	with	unexplained	
asymptomatic	true	hypercalcemia	should	be	
screened	for	primary	hyperparathyroidism	
(pHpT)	and	malignancy	using	an	intact	
parathyroid	hormone	(pTH)	level	by	
immunoradioassay	(sor:	C,	expert	
opinion).	other	recommended	tests	that	
can	distinguish	pHpT	from	malignancy	and	
familial	hypocalciuric	hypercalcemia,	as	well	
as	help	manage	patients	with	pHpT	include	
urinary	24-hour	calcium	and	creatinine	
levels,	parathyroid	hormone	related	peptide	
(pTHrp),	alkaline	phosphatase,	calcitriol,	
and	bone	densitometry	(sor:	C,	expert	
opinion).
Clinical commentary
Choose tests carefully to reduce  
false positives 
Including	serum	calcium	measurements	
in	the	chemistry	panels	that	physicians	
use	to	manage	common	conditions	
such	as	hypertension	has	resulted	in	an	
epidemic	of	incidental	hypercalcemia.	
Tempting	as	it	may	be	to	ignore	these	
unexpected	numbers,	they	point	to	a	
significant	underlying	condition	in	some	
patients.	This	puts	the	family	physician	
in	a	familiar	clinical	position—having	to	
worry	a	patient	just	enough	to	convince	
him	to	consent	to	a	careful,	stepwise	
evaluation	while	somehow	reassuring	him	
that	usually	no	problem	is	found.	The	best	
solution	is	to	order	each	test	for	a	reason,	
which	would	reduce	the	number	of	false	
positives	that	we	spend	so	much	time	
chasing.	
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z Evidence summary
Make sure it’s true hypercalcemia
Measuring calcium levels in asymptom-
atic patients often leads to false-positive 
elevations caused by random error or 
changes in the level of physiologically 
active calcium because of alterations in 
blood pH or serum albumin. Serum cal-
cium levels between 10.0 and 12.0 mg/dL 
indicate mild hypercalcemia; levels >14.0 
mg/dL are severe. Because changes in pH 
and serum albumin levels alter levels of 
physiologically active calcium, authori-
tative sources recommend measuring or 
calculating physiologically active calcium 
if blood pH or albumin is abnormal.1,2 To 
determine the level, use the equation [4.0 
– (plasma albumin)] × 0.8 + (serum calci-
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um) or measure serum ionized calcium.2 
Normal levels of  serum ionized calcium 
for adults older than 19 years are 1.13 to 
1.32 mmol/L, although the exact range 
can vary from laboratory to laboratory. 
Elevated physiologically active calcium 
indicates true hypercalcemia.
Assess for the most common 
causes, PHPT and malignancy
Evaluation of the patient with true hyper-
calcemia should include a detailed histo-
ry, physical examination, and assessment 
of risk factors for all causes of hypercal-
cemia.1,2 PHPT and malignancy are the 
two most common causes of asymptom-
atic true hypercalcemia (TABLE).2 
Laboratory evaluation targeting these 
causes, beginning with an intact PTH level, 
is a logical first step.1,2 Persistent hypercal-
cemia in the presence of elevated or inap-
propriately normal PTH concentrations 
confirms the diagnosis of PHPT.3 When 
serum calcium rises, PTH is normally 
suppressed. Normal intact PTH and low 
24-hour urinary calcium excretion distin-
guishes patients with PHPT from those 
with less common familial hypocalciuric 
hypercalcemia.1,2 
Most patients with PHPT are as-
ymptomatic, although some eventually 
develop bone loss, nephrolithiasis, and 
renal colic.4,5 A 10-year prospective co-
hort study of patients with PHPT found 
that 21% of asymptomatic patients de-
veloped decreased bone density at one 
or more sites.6 None acquired kidney 
stones, but hypercalcemia and hypercal-
ciuria did worsen in 10 of 52 patients. 
A guideline and a review on PHPT rec-
ommend measuring creatinine clearance 
and obtaining a bone densitometry study 
of the distal third of the radius, hip, and 
lumbar spine to assess for end-organ 
changes related to the condition; declin-
ing renal function and osteoporosis may 
be indications for surgery.3,5
Malignancy is the most common 
cause of low intact PTH and true hy-
percalcemia, especially when the calci-
um level is >14 mg/dL.1 A PTHrP >1.0 
pmol/L is highly specific for malignan-
cy because this level does not occur in 
healthy people.1 In a prospective case se-
ries of patients with hypercalcemia and 
malignancy, 54% had elevated PTHrP 
levels.7 The authors found that an el-
evated PTHrP in patients younger than 
65 years of age doubles the risk of death 
from malignancy compared to patients 
the same age with normal PTHrP (haz-
ard ratio=1.9; 95% CI, 1.1-3.4). 
Identify less common causes
Serum calcitriol in association with a 
low intact PTH level and elevated cal-
cium lower than 14 mg/dL helps differ-
entiate the less common causes of hy-
percalcemia. Calcitriol is high in granu-
lomatous diseases such as sarcoidosis, 
tuberculosis, and histoplasmosis, and 
normal in hyperthyroidism and Addi-
son’s disease.1 
Immobilization as a cause of hyper-
calcemia can be distinguished from PHPT 
by history and normal PTH levels and 
from malignancy by a normal alkaline 
phosphatase level.1 
Primary hyperparathyroidism
malignancy  
•	Hematologic	cancers	(non-Hodgkin’s	lymphoma,	multiple	myeloma,	leukemia)	
•	squamous	cell	carcinomas	(lung,	esophagus,	cervix,	vulva,	skin)	
•	Adenocarcinomas	(breast,	kidneys,	ovaries,	bladder)
•	parathyroid	carcinoma
Chronic renal failure
Endocrine disorders	(hyperthyroidism,	pheochromocytoma,		
Addison’s	disease)
familial hypocalciuric hypercalcemia
immobilization
laboratory artifact resulting from altered albumin concentration or ph
medications (vitamin	A	toxicity	[dietary	fads,	isotretinoin	overdose],		
estrogens,	antiestrogens,	thiazides,	lithium)
milk alkali syndrome
Vitamin D toxicity	(granulomatous	disease	[sarcoidosis,	tuberculosis],		
vitamin	D	supplementation)
Based	on	Hutton	e,1	and	Carroll	MF	et	al.2
taBlE
Causes of hypercalcemia
A parathyroid 
hormone-related 
peptide level  
>1.0 pmol/L is 
highly specific  
for malignancy
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Recommendations
In addition to the recommendations dis-
cussed previously, Williams Textbook 
of Endocrinology advises repeating the 
initial calcium level twice and measur-
ing serum BUN, creatinine, electrolytes, 
albumin, globulin, and phosphate.8 The 
authors recommend a generalized work-
up for malignancy, including mammog-
raphy, chest radiography with or with-
out CT, abdominal CT, serum and urine 
immunoelectrophoresis, and temporary 
discontinuation of lithium for patients 
taking the drug. They also recommend 
using PTHrP only when PTH is sup-
pressed but an underlying malignancy 
can’t be found. n
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